These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12781434)

  • 1. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
    Okamoto I; Fujii K; Matsumoto M; Terasaki Y; Kihara N; Kohrogi H; Suga M
    Lung Cancer; 2003 Jun; 40(3):339-42. PubMed ID: 12781434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
    Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
    Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].
    Ieki R; Saitoh E; Hashimoto E; Ohta T; Yuasa K; Iguchi M; Okamura T; Shibuya M; Moriyama S; Goto H
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):977-80. PubMed ID: 12894713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
    Araki J; Okamoto I; Suto R; Ichikawa Y; Sasaki J
    Lung Cancer; 2005 Apr; 48(1):141-4. PubMed ID: 15777982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
    Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surprise phase III failure for ZD1839.
    Wilkinson E
    Lancet Oncol; 2002 Oct; 3(10):583. PubMed ID: 12372708
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
    Giuliani J; Martelli S; Remo A; Bonetti A
    Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
    LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
    Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
    Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
    Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZD1839 (Iressa): what's in it for the patient?
    Natale RB; Zaretsky SL
    Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
    Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.